2019
Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial
Velazquez E, Ambrosy A, Morrow D, McCague K, Duffy C, O'Brien T, Rocha R, DeVore A, Braunwald E. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. Journal Of Cardiac Failure 2019, 25: s80. DOI: 10.1016/j.cardfail.2019.07.227.Peer-Reviewed Original ResearchAcute decompensated HFPIONEER-HF trialHeart failureNT-proBNPBlack patientsPg/mLAngioedema eventsHospital initiationClinical outcomesAcute decompensated heart failureAngiotensin receptor neprilysin inhibitorPre-specified subgroup analysisPrior heart failureACEI/ARBDecompensated heart failureNatriuretic peptide levelsSacubitril/valsartanImproved clinical outcomesSelf-reported raceCV deathEnalapril armHemodynamic stabilizationSymptomatic hypotensionRenal functionNeprilysin inhibitor
2008
Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study)
Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). The American Journal Of Cardiology 2008, 101: 607-612. PMID: 18308007, DOI: 10.1016/j.amjcard.2007.09.115.Peer-Reviewed Original ResearchConceptsRight ventricular fractional area changeVentricular fractional area changeRight ventricular functionHeart failureFractional area changeMyocardial infarctionClinical outcomesSudden deathCause mortalityVentricular dysfunctionEjection fractionVentricular functionBaseline right ventricular functionRight ventricular systolic functionSevere right ventricular dysfunctionLeft ventricular ejection fractionRecurrent myocardial infarctionRight ventricular dysfunctionLeft ventricular dysfunctionVentricular systolic functionVentricular ejection fractionMajor risk factorTwo-dimensional echocardiogramsCV deathCV outcomes
2006
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial
Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006, 3: 313-316. PMID: 16500304, DOI: 10.1016/j.hrthm.2005.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCohort StudiesElectrocardiographyFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeSurvival RateTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsQRS durationSudden deathCV deathAdverse outcomesMyocardial infarctionPost-myocardial infarction settingUnivariate relative riskLeft ventricular dysfunctionHeart failure patientsSymptoms of HFAcute myocardial infarctionDevelopment of HFEnd-systolic volumeLarger ventricular volumesQRS duration prolongationRecurrent MICardiovascular deathInitial electrocardiogramVentricular dysfunctionAcute MIFailure patientsSystolic functionEjection fractionIndependent predictorsClinical outcomes